NCT00131742
Completed
Phase 3
A Phase III Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B
ConditionsChronic Hepatitis B
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Chronic Hepatitis B
- Sponsor
- Novartis
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
This study is being conducted to compare the effectiveness and safety of telbivudine (LdT) and lamivudine in Chinese adults.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Documented clinical history compatible with chronic hepatitis B infection
- •Other protocol-defined inclusion criteria may apply
Exclusion Criteria
- •Patient is pregnant or breastfeeding
- •Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV
- •Patient has previously received lamivudine or any investigational anti-HBV nucleoside or nucleotide analog
- •Other protocol-defined exclusion criteria may apply
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.Hepatitis BCirrhosisNCT00275652Mayo Clinic6
Completed
Phase 3
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis BChronic Hepatitis BNCT00057265Novartis
Completed
Phase 3
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of CirrhosisHepatitisHepatitis B, ChronicCirrhosisNCT00076336Novartis Pharmaceuticals232
Completed
Phase 3
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis BChronic Hepatitis BNCT00115245Novartis
Completed
Phase 2
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV DrugsHIV InfectionsNCT00004852Glaxo Wellcome